Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 17;22(4):1980.
doi: 10.3390/ijms22041980.

Peripheral Neuropathy under Oncologic Therapies: A Literature Review on Pathogenetic Mechanisms

Affiliations
Review

Peripheral Neuropathy under Oncologic Therapies: A Literature Review on Pathogenetic Mechanisms

Mariarita Laforgia et al. Int J Mol Sci. .

Abstract

Peripheral neurologic complications are frequent adverse events during oncologic treatments and often lead to dose reduction, administration delays with time elongation of the therapeutic plan and, not least, worsening of patients' quality of life. Experience skills are required to recognize symptoms and clinical evidences and the collaboration between different health professionals, in particular oncologists and hospital pharmacists, grants a correct management of this undesirable occurrence. Some classes of drugs (platinates, vinca alkaloids, taxanes) typically develop this kind of side effect, but the genesis of chemotherapy-induced peripheral neuropathy is not linked to a single mechanism. This paper aims from one side at summarizing and explaining all the scattering mechanisms of chemotherapy-induced peripheral neuropathy through a detailed literature revision, on the other side at finding new approaches to possible treatments, in order to facilitate the collaboration between oncologists, hematologists and hospital pharmacists.

Keywords: anti-cancer drugs; chemotherapy-induced peripheral neuropathy; mechanism; neurodegeneration; neurotoxicity; pharmacology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Abraira V.E., Ginty D.D. The Sensory Neurons of Touch. Neuron. 2013;79:618–639. doi: 10.1016/j.neuron.2013.07.051. - DOI - PMC - PubMed
    1. Bernhardson B.-M., Tishelman C., Rutqvist L.E. Chemosensory Changes Experienced by Patients Undergoing Cancer Chemotherapy: A Qualitative Interview Study. J. Pain Symptom Manag. 2007;34:403–412. doi: 10.1016/j.jpainsymman.2006.12.010. - DOI - PubMed
    1. Jones D., Zhao F., Brell J., Lewis M.A., Loprinzi C.L., Weiss M., Fisch M.J. Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer. J. Cancer Surviv. 2014;9:1–10. doi: 10.1007/s11764-014-0379-x. - DOI - PMC - PubMed
    1. Kolb N.A., Smith A.G., Singleton J.R., Beck S.L., Stoddard G.J., Brown S., Mooney K. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling. JAMA Neurol. 2016;73:860–866. doi: 10.1001/jamaneurol.2016.0383. - DOI - PMC - PubMed
    1. Banach M., Juranek J.K., Zygulska A.L. Chemotherapy-induced neuropathies-a growing problem for patients and health care providers. Brain Behav. 2016;7:e00558. doi: 10.1002/brb3.558. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources